HomeAI · summaries
Storia in 5 fonti
Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
astrazeneca.com
Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with…
- ·
biopharmadive.com
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in…
- ·
healio.com
Baxfendy approved for uncontrolled hypertension
AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard care.Baxdrostat (Baxfendy) is the first aldosterone synthase…
- ·
morningstar.com
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
- ·
medpagetoday.com
FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients
Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives